Not in steroid refractory GVHD they won't. For at least 7 years anyways.
Take off the rose coloured glasses mate it goes both ways you know, if msb doesn't affect your trial because your aiming for a different group of patients then your trial if successful next decade won't affect their current approval or their trial with adults.
Wish you all good luck but your not going to put msb out of business anytime soon.
@Artephius
Why Orphan Drug Designation for mesoblast is IRRELEVANT to Cynata, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
16.5¢ |
Change
-0.005(2.94%) |
Mkt cap ! $37.28M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.0¢ | 16.5¢ | $39.66K | 238.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 277684 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 14285 | 1 |
View Market Depth
| Last trade - 16.10pm 16/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |